Physician profile
Andriy Golubenko
NPI 1093469215
$887.36
in general payments reported to CMS, 2019-2025
11 companies · $23.01 in 2025
The $23.01 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $416 · 2023: $80.78 · 2024: $368 · 2025: $23.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $169.12 | 2022-2024 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $148.89 | 2022-2024 | Farxiga |
| Ardelyx, INC. | $141.29 | 2024 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $121.88 | 2022-2024 | Jynarque |
| Glaxosmithkline, LLC. | $83.30 | 2024 | Jesduvroq |
| Bayer Healthcare Pharmaceuticals INC. | $67.57 | 2022-2023 | |
| Fresenius USA Marketing, INC. | $61.10 | 2022-2025 | Velphoro, Velphoro, Korsuva |
| Ani Pharmaceuticals, INC. | $29.20 | 2024 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $28.85 | 2022 | |
| Aurinia Pharma U.S., INC. | $21.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.61 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andriy Golubenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.